Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2021 11:41 ET | Source: Gradalis, Inc.

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer

Results from pre-planned subgroup analysis of stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type (BRCA-wt) profile and homologous recombination proficiency (HRP) have been...
January 07, 2021 07:00 ET | Source: Gradalis, Inc.

Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology

The VITAL study, published in The Lancet Oncology, demonstrates that Vigil first-line maintenance treatment resulted in improved RFS in BRCA1/2-wt ovarian cancer when compared to placebo.Importantly...
March 04, 2019 13:14 ET | Source: Gradalis, Inc.

Gradalis Announces Medical Leadership Team Promotion

DALLAS, March 04, 2019 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications,...
November 09, 2018 10:04 ET | Source: Gradalis, Inc.

Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group

DALLAS, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications,...
August 28, 2018 19:16 ET | Source: Gradalis, Inc.

Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma

– The open-label trial will measure progression free survival of participants from date of randomization until first disease progression in the study – – The trial will use product produced from...
May 04, 2016 08:30 ET | Source: Gradalis, Inc.

Gradalis, Inc. Appoints Sunil Joshi Chief Executive Officer

DALLAS, May 04, 2016 (GLOBE NEWSWIRE) -- Gradalis, Inc. today announced the appointment of Sunil Joshi as Chief Executive Officer. Mr. Joshi is a highly experienced Pharma/Biotech business...
April 26, 2016 09:15 ET | Source: Gradalis, Inc.

Gradalis, Inc. Announces Initiation of a Phase 2 Study using Gradalis’ Vigil® Immunotherapy in Combination with Anti-PD-1 Technology to Treat Patients with Advanced Non-Small Cell Lung Cancer

DALLAS, April 26, 2016 (GLOBE NEWSWIRE) -- Gradalis Inc., a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 2 study for the treatment of patients with advanced...
July 09, 2015 09:15 ET | Source: Gradalis, Inc.

Gradalis, Inc. Announces Initiation of a Phase 2b Study of Vigil(TM) Cancer Vaccine in Ewing’s Sarcoma

DALLAS, July 09, 2015 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 2b study for its proprietary, personalized cancer...
June 04, 2015 09:15 ET | Source: Gradalis, Inc.

Gradalis, Inc. Announces Presentation of Data From a Pilot Study of Vigil (TM) Cancer Vaccine in Ewing’s Sarcoma

DALLAS, June 04, 2015 (GLOBE NEWSWIRE) -- Gradalis Inc., a clinical-stage biopharmaceutical company, today announced that data from a pilot study for its proprietary personalized cancer vaccine,...
April 13, 2015 14:51 ET | Source: Gradalis, Inc.

Gradalis, Inc. Announces Presentation of Phase 2 Data of Ovarian Cancer Patients Treated With Vigil(TM)

DALLAS, April 13, 2015 (GLOBE NEWSWIRE) -- Gradalis Inc., a late-stage biopharmaceutical company, today announced that Phase 2 data for its proprietary personalized immunotherapy, Vigil™ (previously...